Priming by DNA immunization augments T-cell responses induced by modified live bovine herpesvirus vaccine.
DNA vaccines have several advantages over conventional vaccines. One of the most important characteristics is the presentation of antigen via both MHC class I and class II receptors. Although this generally results in strong T-cell responses, antibody production and protection achieved by DNA immunization are unfortunately not always adequate. In contrast, modified live virus (MLV) vaccines usually induce adequate antibody and moderate cellular responses, whereas killed vaccines tend to elicit weak immune responses in general. A DNA prime-MLV boost regimen should result in enhanced cellular immunity and possibly improved antibody production. To test this hypothesis, plasmids encoding bovine herpesvirus-1 (BHV-1) glycoproteins B and D were delivered by gene gun to the genital mucosa of cattle prior to immunization with modified live BHV-1 vaccine. The immune responses induced were compared to those of an MLV-vaccinated group and a negative control group. Although significantly enhanced T-cell responses were induced by priming with the DNA vaccine, there was no increase in antibody titres. Similar levels of protection were induced by the MLV vaccine alone and the DNA prime and MLV boost regimen, which suggests that there is no correlation between the induction of T-cell responses and protection from BHV-1 challenge.
Loehr
B I
BI
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
Pontarollo
R
R
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
Rankin
R
R
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
Latimer
L
L
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
Willson
P
P
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
Babiuk
L A
LA
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
van Drunen Littel-van den Hurk
S
S
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd, Saskatoon, Saskatchewan, CanadaS7N 5E31.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D019470:Biolistics; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology* / Q000517:prevention & control; D002455:Cell Division; D005260:Female; D006023:Glycoproteins / Q000235:genetics; D006566:Herpesviridae Infections / Q000662:veterinary*; D007242:Herpesvirus 1, Bovine / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D010957:Plasmids; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics
D000914:Antibodies, Viral; D006023:Glycoproteins; D022283:Herpesvirus Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014764:Viral Proteins